Boehringer Ingelheim Pharmaceuticals, Inc.
NEWS
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
Three companies have posted major developments in the field of heart disease therapy.
It was another busy week for clinical trial news. Here’s a look.
The U.S. FDA greenlit a new indication for Gilead Sciences’ drug Biktarvy for pediatric patients with HIV who are virologically suppressed or new to antiretroviral therapy.
The European Society for Medical Oncology Congress 2021 runs from September 16–21, 2021. Here’s a preview of some of the presentations at the meeting.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
JOBS
IN THE PRESS